Cargando…

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

BACKGROUND: Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitumor activity. The objective of this trial was to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yap, Timothy A, Bessudo, Alberto, Hamilton, Erika, Sachdev, Jasgit, Patel, Manish R, Rodon, Jordi, Evilevitch, Lena, Duncan, Meghan, Guo, Wei, Kumar, Sujatha, Lu, Sharon, Dezube, Bruce J, Gabrail, Nashat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948406/ https://www.ncbi.nlm.nih.gov/pubmed/35332062 http://dx.doi.org/10.1136/jitc-2021-003924

Ejemplares similares

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Focusing with quadrupoles, doublets and triplets
por: Regenstreif, E
Publicado: (1964)

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
por: Garon, Edward B, et al.
Publicado: (2016)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Back to the doublet-triplet splitting problem
por: Barbieri, Riccardo, et al.
Publicado: (1993)

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

Natural triplet-doublet splitting from supergravity
por: Kounnas, Costas, et al.
Publicado: (1983)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

Rescuing doublets into triplets in Pooh-Hydra geometry program
por: Yaffe, R
Publicado: (1974)

Singlet-doublet/triplet dark matter and neutrino masses
por: Fiaschi, Juri, et al.
Publicado: (2019)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
por: Patnaik, Amita, et al.
Publicado: (2021)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Locally supersymmetric SO(10) with natural doublet/triplet splitting
por: Maalampi, J, et al.
Publicado: (1983)

Doublet-Triplet Splitting in Realistic Heterotic String Derived models
por: Faraggi, Alon E.
Publicado: (2001)

Insights into centriole geometry revealed by cryotomography of doublet and triplet centrioles
por: Greenan, Garrett A, et al.
Publicado: (2018)

Light colour-triplet Higgs is compatible with proton stability: an alternative approach to the doublet-triplet splitting problem
por: Dvali, Gia
Publicado: (1995)

Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series
por: Gabrail, Nash, et al.
Publicado: (2020)

A Solution to the Doublet-Triplet Splitting Problem in the Type IIB Supergravity
por: Watari, T, et al.
Publicado: (2002)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
por: Yu, Jing, et al.
Publicado: (2015)

Remarks on the phase acceptance of a quadrupole multiplet application to the doublet and the symmetric triplet
por: Regenstreif, E
Publicado: (1969)

Focusing and magnification ratio adjustments with quadrupole triplets and doublets: Programme for the IBM 7090
por: Madsen, J H B
Publicado: (1964)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma
por: Balakrishnan, Ilango, et al.
Publicado: (2022)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Singlet and triplet to doublet energy transfer: improving organic light-emitting diodes with radicals
por: Li, Feng, et al.
Publicado: (2022)

Niraparib for ovarian cancer
Publicado: (2021)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
por: Dell’Aquila, E., et al.
Publicado: (2022)

BALD-2: a mutation affecting the formation of doublet and triplet sets of microtubules in Chlamydomonas reinhardtii
Publicado: (1975)

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
por: Tao, Wanjun, et al.
Publicado: (2020)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

Spectral features of the tunneling-induced transparency and the Autler-Townes doublet and triplet in a triple quantum dot
por: Luo, Xiao-Qing, et al.
Publicado: (2018)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis
por: Zhang, Li, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
por: Klavans, Madison R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5le20tfnd44qn2qsp8f566gomc